It has nothing to do with what percentage split IPCI has with MNK. We were all basing our Q3 estimates based entirely on the Bloomberg weekly updates.
Based entirely on the reported Bloomberg numbers on PAR/FocalinXR alone in line with Bloomberg's reported Q2 PAR/FocalinXR sales...IPCI should've attained $1.7M in revenue from the PAR deal alone.(If the Bloomberg numbers were even remotely accurate which they're clearly not)
So right now none of us even have 1 clue how much FocalinXR PAR sold during IPCI's fiscal Q3 or how much SeroquelXR MNK sold during the same Q.
All we know for sure is that PAR's FocalinXR sales tumbled off the cliff during the Q...which makes sense on 2 fronts despite what the erroneous Bloomberg numbers suggested. 1st, PAR lost exclusivity on 4 strengths of FocalinXR for the final 2 months of IPCI's Q3...and MNK didn't even launch SeroquelXR til halfway through the Q and even then their rollout was super slow.
So the $1.2M revenue reported is actually perfectly appropriate with the only reason most here had expected/anticipated at least $2M in revenue for the Q being the faulty Bloomberg numbers most of us were relying on.
Market Data 
Markets 
AI
